09:14 AM EST - Oncolytics Biotech Inc : Received regulatory clearance to evaluate Pelareorep in combination with modified FOLFIRINOX +/- an anti-PD-L1 inhibitor in pancreatic cancer. US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study. The first patient expected to be enrolled in Q2 2024. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.62.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=5923811266767728
